Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504727 | 0.82 | S1PR1 (0.45) | MMP12 | |
| SCHEMBL6500407 | 0.82 | ACACB (0.43) | MMP12TDP1 | |
| SCHEMBL6530111 | 0.79 | SRC (0.38) | MMP12MMP13CYP11B1CYP11B2 | |
| SCHEMBL6528946 | 0.78 | THRA (0.39) | MMP12DPP4MMP13TDP1 | |
| SCHEMBL6528900 | 0.77 | MMP12 (0.39) | MMP12 | |
| SCHEMBL6529849 | 0.77 | MMP12 (0.35) | MMP12 | |
| SCHEMBL6527581 | 0.76 | MMP12 (0.36) | MMP12 | |
| SCHEMBL6527017 | 0.76 | MMP12 (0.40) | MMP12 | |
| SCHEMBL6531215 | 0.76 | ESR1 (0.37) | MMP12 | |
| SCHEMBL6530514 | 0.76 | FDFT1 (0.41) | MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |